Danish researchers examined data from more than 77,000 people using anti-obesity medications without diabetes. They discovered that 52 percent discontinued treatment within one year. Eighteen percent quit within three months, 31 percent within six months, and 42 percent within nine months. The team highlighted that younger adults, men, and people living in poorer communities stopped the drugs most frequently.
Costs, Side Effects, and Demographics Drive Dropouts
Patients under 30 were 48 percent more likely to quit than those aged 45 to 59. People in low-income areas were 14 percent more likely to stop compared to residents of wealthier neighborhoods. Men also showed higher dropout rates than women. The researchers noted that prior use of psychiatric or gastrointestinal medications may indicate unpleasant side effects like nausea or vomiting influenced decisions to quit.
A month’s supply of Ozempic costs up to €313 in Denmark without diabetes coverage, compared to €120 in Germany. Researchers linked these high costs to reduced adherence, especially among people with limited financial resources.
Long-Term Treatment Critical for Effectiveness
Ozempic and Wegovy belong to the GLP-1 receptor agonist class. These drugs mimic hormones that suppress appetite and support weight loss. Patients who stop treatment often regain lost weight, sparking debate about lifelong use.
Professor Reimar W. Thomsen from Aarhus University emphasized the importance of ongoing treatment. “These medications lose all appetite control benefits once discontinued,” he said. He argued that strategies must focus on keeping patients engaged to maximize long-term health gains.
Broader Implications for Public Health
Thomsen stressed that more must be done to support patients who benefit from these treatments. Research shows these drugs lower risks of heart disease, cancer, and addiction. With over half of European adults overweight or obese, adherence strategies remain crucial. The findings, set for presentation at the European Association for the Study of Diabetes meeting in Vienna, aim to influence future health policies and clinical practices.
